Akash, Gaucher disease, India
Sanofi’s Rare Humanitarian Program is the first humanitarian initiative of its kind for people with lysosomal storage disorders – a group of rare genetic conditions caused by enzyme deficiencies. The program provides access to free treatments for patients who meet the program’s criteria who otherwise would not have access to such treatments. Established in 1991 when our first treatment for Gaucher disease was approved by the U.S. FDA, the program has evolved and expanded to support five different lysosomal storage disorder communities, including Gaucher disease, Fabry disease, Pompe disease, and mucopolysaccharidoses (MPS) I and II across six continents.
Each patient story reflects the real-life experiences of individuals diagnosed with one of the five lysosomal storage disorders noted. Individual patients may experience these diseases differently.
Rare blood disorders (hemophilia)
Sanofi’s humanitarian program for hemophilia is critical as a vast majority of people with this disease have limited or no access to diagnosis and treatment, and many in the developing world often don’t survive to adulthood.
- Together with Sobi™, Sanofi recently expanded its support of the World Federation of Hemophilia (WFH) Humanitarian Aid Program by pledging to donate up to an additional 500 million IUs of factor therapy for up to five years. This brings the total commitment up to an unprecedented 1 billion IUs for humanitarian use-the single largest donation of hemophilia factor therapy in history.
- With Sobi, Sanofi has delivered 538 million IUs to the WFH Humanitarian Aid Program since 2015. More than 17,300 patients in 45 contries have been treated through its donation.
Partnerships for humanitarian aid
Sanofi relies on its partners’ local expertise and relationships to help support patients and navigate the challenges of reaching them in countries around the world.
- Project HOPE
- ANERA (American Near East Refugee Aid)
- Direct Relief
- World Federation of Hemophilia Humanitarian Aid Program, and others.